On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened higher 5.48% from the last session, before settling in for the closing price of $11.49. Price fluctuations for NTLA have ranged from $5.90 to $24.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.04% over the past five years. Company’s average yearly earnings per share was noted 20.54% at the time writing. With a float of $97.43 million, this company’s outstanding shares have now reached $103.54 million.
Let’s look at the performance matrix of the company that is accounted for 403 employees. In terms of profitability, gross margin is 88.67%, operating margin of -1187.36%, and the pretax margin is -1154.1%.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.94%, while institutional ownership is 95.04%. The most recent insider transaction that took place on Jul 23 ’25, was worth 104,617. In this transaction EVP, Chief Financial Officer of this company sold 7,462 shares at a rate of $14.02, taking the stock ownership to the 106,062 shares. Before that another transaction happened on Jul 01 ’25, when Company’s EVP, Chief Technical Officer sold 1,022 for $9.82, making the entire transaction worth $10,036. This insider now owns 95,369 shares in total.
Intellia Therapeutics Inc (NTLA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.65% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 4.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.23, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.87 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 4.94 million, a positive change from its year-to-date volume of 4.05 million. As of the previous 9 days, the stock’s Stochastic %D was 14.21%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 71.41%, which indicates a significant increase from 27.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.88 in the past 14 days, which was higher than the 0.69 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.28, while its 200-day Moving Average is $11.10.
